You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNefazodone
Accession NumberDB01149  (APRD00402)
TypeSmall Molecule
GroupsApproved, Withdrawn
Description

Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia]

Structure
Thumb
Synonyms
1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one
Nefazodona
Nefazodone
Nefazodonum
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lin-nefazodonetablet200 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodonetablet150 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodonetablet100 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodonetablet50 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Serzone-5ht2tablet150 mgoralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2tablet50 mgoralBristol Myers Squibb Canada1997-07-162003-11-28Canada
Serzone-5ht2tablet200 mgoralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2tablet100 mgoralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nefazodone Hydrochloridetablet200 mg/1oralRebel Distributors Corp2003-09-162016-04-05Us
Nefazodone Hydrochloridetablet100 mg/1oralTeva Pharmaceuticals USA Inc2003-09-162016-04-23Us
Nefazodone Hydrochloridetablet150 mg/1oralRebel Distributors Corp2003-09-162016-04-05Us
Nefazodone Hydrochloridetablet100 mg/1oralRebel Distributors Corp2003-09-162016-04-05Us
Nefazodone Hydrochloridetablet100 mg/1oralSTAT Rx USA LLC2010-08-182016-04-05Us
Nefazodone Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2011-06-082016-04-05Us
Nefazodone Hydrochloridetablet50 mg/1oralTeva Pharmaceuticals USA Inc2003-09-162016-04-23Us
Nefazodone Hydrochloridetablet50 mg/1oralAv Kare, Inc.2013-12-162016-04-05Us
Nefazodone Hydrochloridetablet150 mg/1oralTeva Pharmaceuticals USA Inc2003-09-162016-04-23Us
Nefazodone Hydrochloridetablet250 mg/1oralAv Kare, Inc.2013-07-302016-04-05Us
Nefazodone Hydrochloridetablet250 mg/1oralTeva Pharmaceuticals USA Inc2003-09-162016-04-23Us
Nefazodone Hydrochloridetablet250 mg/1oralRebel Distributors Corp2003-09-162016-04-05Us
Nefazodone Hydrochloridetablet200 mg/1oralTeva Pharmaceuticals USA Inc2003-09-162016-04-23Us
Over the Counter ProductsNot Available
International Brands
NameCompany
DutoninNot Available
SerzoneNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nefazodone Hydrochloride
82752-99-6
Thumb
  • InChI Key: DYCKFEBIOUQECE-UHFFFAOYSA-N
  • Monoisotopic Mass: 505.201130739
  • Average Mass: 506.468
DBSALT000406
Categories
UNII59H4FCV1TF
CAS number83366-66-9
WeightAverage: 470.007
Monoisotopic: 469.224453
Chemical FormulaC25H32ClN5O2
InChI KeyInChIKey=VRBKIVRKKCLPHA-UHFFFAOYSA-N
InChI
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
IUPAC Name
1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Substituted aniline
  • Dialkylarylamine
  • Phenol ether
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsNefazodone, an antidepressant synthetically derived phenylpiperazine, is used to treat major depression. Although it is structurally similar to trazodone, nefazodone has a mechanism of action different from other antidepressants and, hence, lacks the risk for major cardiovascular toxicity seen with tricyclics and insomnia and inhibition of REM sleep seen with the selective serotonin reuptake inhibitors.
Mechanism of actionWithin the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
Related Articles
AbsorptionNefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).
Volume of distribution
  • 0.22 to 0.87 L/kg
Protein bindingGreater than 99% (in vitro, human plasma proteins).
Metabolism

Hepatic.

SubstrateEnzymesProduct
Nefazodone
hydroxynefazodoneDetails
Route of eliminationNefazodone is extensively metabolized after oral administration by n-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine.
Half life2-4 hours
ClearanceNot Available
ToxicityCases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9744
Caco-2 permeable+0.5296
P-glycoprotein substrateSubstrate0.5809
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8373
Renal organic cation transporterInhibitor0.5685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7506
CYP450 1A2 substrateNon-inhibitor0.7931
CYP450 2C9 inhibitorInhibitor0.5999
CYP450 2D6 inhibitorNon-inhibitor0.8799
CYP450 2C19 inhibitorNon-inhibitor0.5434
CYP450 3A4 inhibitorNon-inhibitor0.8711
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8028
Ames testNon AMES toxic0.5208
CarcinogenicityNon-carcinogens0.7388
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9067 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8749
hERG inhibition (predictor II)Inhibitor0.7288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg/1
Tabletoral150 mg/1
Tabletoral200 mg/1
Tabletoral250 mg/1
Tabletoral50 mg/1
Tabletoral100 mg
Tabletoral150 mg
Tabletoral200 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Nefazodone hcl 250 mg tablet1.82USD tablet
Nefazodone hcl 200 mg tablet1.78USD tablet
Nefazodone hcl 150 mg tablet1.75USD tablet
Nefazodone hcl 100 mg tablet1.72USD tablet
Nefazodone hcl 50 mg tablet1.68USD tablet
Serzone 100 mg tablet1.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point83.5 °CPhysProp
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0698 mg/mLALOGPS
logP3.71ALOGPS
logP4.65ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area51.62 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity132.38 m3·mol-1ChemAxon
Polarizability51.85 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-zviq200000-49cb6e97c09a9e806dd5View in MoNA
References
Synthesis Reference

DrugSyn.org

US4338317
General References
  1. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
External Links
ATC CodesN06AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Nefazodone can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Nefazodone.
AcetophenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Acetophenazine.
ado-trastuzumab emtansineThe serum concentration of the active metabolites of ado-trastuzumab emtansine can be increased when ado-trastuzumab emtansine is used in combination with Nefazodone.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Nefazodone.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Nefazodone.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Nefazodone.
AmisulprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amisulpride.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nefazodone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nefazodone.
AripiprazoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aripiprazole.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Nefazodone.
AtazanavirThe serum concentration of Nefazodone can be increased when it is combined with Atazanavir.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Nefazodone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nefazodone.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Nefazodone.
BatimastatThe serum concentration of Nefazodone can be increased when it is combined with Batimastat.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Nefazodone.
BenzquinamideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Benzquinamide.
BexaroteneThe serum concentration of Nefazodone can be decreased when it is combined with Bexarotene.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Nefazodone.
BosentanThe serum concentration of Nefazodone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nefazodone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nefazodone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nefazodone.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Nefazodone.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Nefazodone.
BuspironeBuspirone may increase the serotonergic activities of Nefazodone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nefazodone.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Nefazodone.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nefazodone.
CarphenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Carphenazine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Nefazodone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorprothixene.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nefazodone.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Nefazodone.
ClozapineThe metabolism of Clozapine can be decreased when combined with Nefazodone.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nefazodone.
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nefazodone.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nefazodone.
DabrafenibThe serum concentration of Nefazodone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Nefazodone.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Nefazodone.
DarunavirThe serum concentration of Nefazodone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Nefazodone.
DeferasiroxThe serum concentration of Nefazodone can be decreased when it is combined with Deferasirox.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Nefazodone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nefazodone.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nefazodone.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nefazodone.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nefazodone.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nefazodone.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Nefazodone.
DroperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Nefazodone.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Nefazodone.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nefazodone.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nefazodone.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Nefazodone.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nefazodone.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Nefazodone.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Nefazodone.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nefazodone.
FencamfamineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fencamfamine.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Nefazodone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nefazodone.
FluconazoleThe metabolism of Nefazodone can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Nefazodone.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Nefazodone.
FluoxetineThe metabolism of Nefazodone can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluspirilene.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Nefazodone.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nefazodone.
FosamprenavirThe serum concentration of Nefazodone can be increased when it is combined with Fosamprenavir.
Fusidic AcidThe serum concentration of Nefazodone can be increased when it is combined with Fusidic Acid.
GranisetronGranisetron may increase the serotonergic activities of Nefazodone.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Nefazodone.
HaloperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Haloperidol.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nefazodone.
IdelalisibThe serum concentration of Nefazodone can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nefazodone resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nefazodone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nefazodone.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Nefazodone.
IndinavirThe serum concentration of Nefazodone can be increased when it is combined with Indinavir.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nefazodone.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nefazodone.
IsoflurophateThe serum concentration of Nefazodone can be increased when it is combined with Isoflurophate.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Nefazodone.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Nefazodone.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Nefazodone.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Nefazodone.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Nefazodone.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Nefazodone.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Nefazodone.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nefazodone.
LinezolidLinezolid may increase the serotonergic activities of Nefazodone.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nefazodone.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nefazodone.
LoxapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Loxapine.
LuliconazoleThe serum concentration of Nefazodone can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Nefazodone.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Nefazodone.
MACITENTANThe serum concentration of MACITENTAN can be increased when it is combined with Nefazodone.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Nefazodone.
Medroxyprogesterone AcetateThe serum concentration of Medroxyprogesterone Acetate can be increased when it is combined with Nefazodone.
MesoridazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Methotrimeprazine.
Methylene blueNefazodone may increase the serotonergic activities of Methylene blue.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone.
MetoclopramideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Metoclopramide.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Nefazodone.
MitotaneThe serum concentration of Nefazodone can be decreased when it is combined with Mitotane.
MolindoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Molindone.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nefazodone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Nefazodone can be increased when it is combined with Netupitant.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nefazodone.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nefazodone.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.
OlanzapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Nefazodone.
OndansetronThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ondansetron.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Nefazodone.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Nefazodone.
OxycodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Oxycodone.
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Nefazodone.
PaliperidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nefazodone.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Nefazodone.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Nefazodone.
ParoxetineParoxetine may increase the serotonergic activities of Nefazodone.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nefazodone.
Peginterferon alfa-2bThe serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.
PerphenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Perphenazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nefazodone.
PhenytoinThe metabolism of Nefazodone can be increased when combined with Phenytoin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Nefazodone.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nefazodone.
PiperacetazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Piperacetazine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nefazodone.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Nefazodone.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nefazodone resulting in a loss in efficacy.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nefazodone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Promazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Nefazodone.
QuetiapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Quetiapine.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Nefazodone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nefazodone.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Nefazodone.
RemoxiprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Nefazodone.
ReserpineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Reserpine.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Nefazodone.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nefazodone.
RisperidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Risperidone.
RitonavirThe serum concentration of Nefazodone can be increased when it is combined with Ritonavir.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nefazodone.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Nefazodone.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Nefazodone.
SaquinavirThe serum concentration of Nefazodone can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Nefazodone.
SertindoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sertindole.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Nefazodone.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.
SiltuximabThe serum concentration of Nefazodone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Nefazodone.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nefazodone.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Nefazodone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nefazodone.
St. John's WortThe serum concentration of Nefazodone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Nefazodone can be increased when it is combined with Stiripentol.
SulpirideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Nefazodone.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nefazodone.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Nefazodone.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Nefazodone.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Nefazodone.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Nefazodone.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Nefazodone.
ThioridazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thiothixene.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nefazodone resulting in a loss in efficacy.
TiclopidineThe metabolism of Nefazodone can be decreased when combined with Ticlopidine.
TipranavirThe serum concentration of Nefazodone can be increased when it is combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nefazodone.
TocilizumabThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Nefazodone.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Nefazodone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nefazodone.
ToremifeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Nefazodone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nefazodone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nefazodone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Triflupromazine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nefazodone.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Nefazodone.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Nefazodone.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nefazodone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nefazodone.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Nefazodone.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Nefazodone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ziprasidone.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Nefazodone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid avocado.
  • Limit garlic, ginger, gingko, and horse chestnut.
  • Take this medication either consistently with or without food as instructed by your doctor.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Hidalgo R, Hertzberg MA, Mellman T, Petty F, Tucker P, Weisler R, Zisook S, Chen S, Churchill E, Davidson J: Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol. 1999 Mar;14(2):61-8. [PubMed:10220119 ]
  2. Meyer JH, Cho R, Kennedy S, Kapur S: The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology (Berl). 1999 Jun;144(3):279-81. [PubMed:10435395 ]
  3. Horton JC, Trobe JD: Akinetopsia from nefazodone toxicity. Am J Ophthalmol. 1999 Oct;128(4):530-1. [PubMed:10577608 ]
  4. Eckler JR, Rabin RA, Winter JC: Nefazodone in the rat: mimicry and antagonism of [-]-DOM-induced stimulus control. Pharmacol Biochem Behav. 2003 May;75(2):405-10. [PubMed:12873632 ]
  5. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J: Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003 Oct;23(5):509-13. [PubMed:14520130 ]
  6. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  8. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80. [PubMed:7475971 ]
  2. Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC: Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol. 1998 Feb;18(1):67-71. [PubMed:9472845 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  5. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80. [PubMed:7475971 ]
  2. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD: Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res. 1999 Jul 30;87(1):1-5. [PubMed:10512149 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  5. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. [PubMed:10445380 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. [PubMed:10445380 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:24